[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: Search published articles ::
Showing 5 results for Kazemian

F. Farhan, A. Kazemian, H. Alagheband,
Volume 1, Issue 2 (9-2003)
Abstract

Background: Radioprotective capability of histamine H2 receptor antagonists have been shown in several in vivo studies mainly using animal models. However, to verify the effectiveness of these agents in clinical applications, studies should be performed on human cells. In the present study radioprotective properties of these agents was examined in vitro on human lymphocytes using metaphase analysis.

Materials and Methods : In vitro metaphase analysis technique was used to test the effects of cimetidine, ranitidine and famotidine on radiation induced clastogenic effects. Lymphocytes in whole peripheral blood were exposed to 3 Gy gamma-rays at a dose rate of 73.7 cGy/min in the presence or absence of various doses of the drugs used in this study. The frequency of chromosomal aberrations were determined after standard metaphase preparations and staining slides in 5% Giemsa.

Results: Results show that radiation produced a high number of chromosomal aberrations in lymphocytes compared to controls (p<0.001). All three drugs used in this study effectively reduced the frequency of chromosomal aberrations at all doses. Famotidine was found to be more effective than the other two drugs.

Conclusion: From the results obtained it can be concluded that H 2 -receptor antagonists used in this study effectively reduced the clastogenic effects of radiation with a dose reduction factor (DRF) of 1.5-2 in human lymphocytes in vitro. The way in which these drugs reduce the clastogenic effects of radiation might be via radical scavenging mechanism. Iran . J. Radiat. Res. 2003 1(2): 99 – 104.
A. Kazemian, H.r. Dehghan Manshadi, M. Sardari Kermani,
Volume 2, Issue 3 (12-2004)
Abstract

Sinonasal teratocarcinosarcoma (SNTCS) is a rare tumor characterized by mixture architecture of epithelial and mesenchymal components. SNTCS is a highly malignant tumor displaying progressive and aggressive growth with poor prognosis. Only about 40% of all patients survive after five years. It seems the combination of surgery and radiotherapy currently is the most
effective treatment. In this report we are presenting a 24-year-old Iranian male with SNTCS of right nasal cavity and paranasal sinuses who was referred to our radiotherapeutic Oncology
department, Tehran cancer institute, for post operative radiation treatment. The patient is treated with combination of surgical excision, postoperative radiation therapy and then followed for 10 months. The clinical and pathologic features, as well as its clinical course are presented. SNTSC is a rare condition and rapid progressive tumor. So far, the most widely accepted therapeutic plan for its treatment has been surgical excision with postoperative radiation therapy. Iran . J. Radiat. Res., 2004 2 (3): 159-162


A. Kazemian, Sh. Kamian, M. S. Hoseini, M.r. Azizi,
Volume 3, Issue 3 (12-2005)
Abstract

  ABSTRACT

  Soft tissue sarcomas of the oral cavity are uncommon malignancies those of smooth-muscle origin are extremely rare. Leiomyosarcomas of the tongue are very rare. Either surgery or radiation therapy with or without chemotherapy are the treatment modalities which improve prognosis. We are presenting a 32-year-old man with leiomyosarcoma of the lateral aspect of the oral tongue with neck metastasis, who was referred to our radio therapeutic oncology department after glossectomy and radical modified neck dissection. The clinical and pathologic features together with his clinical course will be discussed. Six months after chemoradiotherapy, he developed a single metastasis in his right femur, and then by features of lung metastasis he died in a few weeks, unfortunately.


S. Tajiki, Ph.d., S. Gholami, A. Kazemian, P. Haddad, M. Esfahani, R. Ghalehtaki, A. Rastjoo, F. Pakniyat, A.s. Meigooni,
Volume 19, Issue 1 (1-2021)
Abstract

In the present study, a case was reported concerning a patient with a bulky extremity soft tissue sarcoma treated with spatially fractionated Grid therapy and then followed by standard external beam radiotherapy. Treatment was performed using a Grid block to deliver 15 Gy in one fraction. There was one week interval break before EBRT treatment with 50 Gy in 25 fractions for the neoadjuvant external beam radiotherapy. The surgery was performed 4 weeks after the completion of radiotherapy. The follow-up time was considered as 24 months. The patient's general condition was good during this period without the presence of tumor recurrence or grade 3 or 4 treatment-related toxicities. Combining different treatment techniques like grid therapy is feasible and may  improve the outcomes in the management of bulky high-grade soft-tissue sarcomas of the extremities.

F. Farhan, S. Mansouri, F. Samiee, A. Kazemian, B. Kalaghchi, M. Lashkari, H. Alizadeh, M.d M. Yamrali,
Volume 20, Issue 4 (10-2022)
Abstract

Background: The main purpose of the present study was to evaluate the safety and efficiency of concurrent administration of hydroxychloroquine (HCQ) and whole brain radiation therapy (WBRT) in patients with brain metastases. Based on numerous preclinical reports, inhibition of autophagy by HCQ can significantly enhance the efficacy of DNA-damaging therapies improving results of radiation therapy. The primary end point of this study was response to treatment and complications, determined by the National Cancer Institute Common Toxic Criteria for Adverse Events (CTCAE) scale V5.0. Material and Methods: Patients with pathologically-confirmed primary solid malignancies together with single or multiple brain metastases on magnetic resonance imaging (MRI) were enrolled in the study (n=64). Treatment with HCQ (200 mg/P.O. once daily) was begun concurrent with WBRT (total dose of 30 Grays (Gy) in 10 daily fractions) in case group. Control group received the standard regimen. Results: Analysis of complications and response rate at each follow up points revealed no statistically significant differences between the case and control groups. Although, median brain metastasis specific Progression Free Survival (PFS) was non-significantly longer in HCQ group compared to control. No grade 3 or more severe toxicities were reported during therapy in both groups of the study. Conclusion: Although concurrent administration of HCQ with WBRT in patients who suffers from brain metastases was well tolerated, this combination did not meaningfully improve outcomes in comparison to WBRT alone.
 
 

Page 1 from 1     

International Journal of Radiation Research
Persian site map - English site map - Created in 0.12 seconds with 41 queries by YEKTAWEB 4714